REMORY, a Supplement Known for Containing Plasmalogens, Which Are Recognized for Their Role in Preventing Cognitive Decline, Now Available in the United States

REMORY: Elevate Cognitive Health with Unique Sea Squirt-Derived Plasmalogens. Now in the U.S., this Japanese-Innovated Supplement Combines EPA, DHA, and Omega-3s for Enhanced Memory and Brain Function in Aging Adults. Recognized by Japan as a ‘Food with Functional Claims,’ REMORY is FDA-Notified, Setting a New Standard in Natural Cognitive Support.

LOS ANGELES, CA / ACCESSWIRE / November 16, 2023 / REMORY®, a supplement known for containing plasmalogens, which are recognized for their role in preventing cognitive decline, has been launched in the United States. Since its introduction in October 2023, the product has received considerable attention.

REMORY®, a supplement known for containing plasmalogens
REMORY®, a supplement known for containing plasmalogens, which are recognized for their role in preventing cognitive decline, now available in the United States

Hokkori USA, a distributor known for its commitment to quality and customer satisfaction, has recently announced its role as the authorized distributor of a health product called REMORY®, a supplement known for containing plasmalogens, which are recognized for their role in preventing cognitive decline manufactured by Moolint, Inc.

REMORY® contains plasmalogens, components also found in the human brain, which play a crucial role in maintaining cognitive function. This supplement is particularly suitable for middle-aged and older adults who experience a decline in memory. Unlike other plasmalogens, REMORY® utilizes plasmalogens derived from sea squirts (ascidians), a source known for its rich content of not only plasmalogens but also EPA, DHA, and Omega-3 fatty acids. The primary ingredient in REMORY® is high-quality sea squirts sourced entirely from Hokkaido, Japan.

Furthermore, REMORY® is the only sea squirt-derived plasmalogen supplement in the U.S. market that has been granted permission by the Japanese Government to be labeled as a “Food with Functional Claims.”

Japan, facing rapid aging compared to other countries globally, has a high demand for products that help maintain memory, and many seniors have experienced the benefits of plasmalogens.

  • REMORY® is a registered trademark in the United States.
  • The sea squirt-derived plasmalogens in REMORY® have obtained a New Dietary Ingredient Notification (NDIN) in the U.S. The NDIN is a registration requirement by the FDA for nutritional components not previously sold as dietary supplements in the U.S.
  • “Food with Functional Claims” refers to a Japanese regulatory system where foods are registered with the Consumer Affairs Agency of Japan, based on scientific evidence for safety and functionality in accordance with Japanese regulations.

Contact Information

Takahito Tsuchiya
Director
info@hokkori-usa.com
310-347-8750

SOURCE: Hokkori USA, Inc.

View source version on accesswire.com:
https://www.accesswire.com/803990/remory-a-supplement-known-for-containing-plasmalogens-which-are-recognized-for-their-role-in-preventing-cognitive-decline-now-available-in-the-united-states

Staff

Recent Posts

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

8 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

11 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

11 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

11 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

11 hours ago

RxAnte Announces Strategic Growth Investment from Primus Capital

PORTLAND, Maine, Jan. 12, 2026 /PRNewswire/ -- RxAnte, the leading provider of analytics, software, and…

11 hours ago